Abstract
Findings from the phase III DESTINY-Breast04 trial indicate that the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) is effective for patients with inoperable/metastatic HER2-low breast cancer. T-DXd should be considered a new standard of care for these patients, who otherwise have limited options.
©2022 American Association for Cancer Research.
Publication types
-
Clinical Trial, Phase III
MeSH terms
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Breast Neoplasms* / drug therapy
-
Breast Neoplasms* / genetics
-
Breast Neoplasms* / pathology
-
Camptothecin / analogs & derivatives
-
Female
-
Humans
-
Immunoconjugates* / therapeutic use
-
Receptor, ErbB-2
-
Trastuzumab / therapeutic use
Substances
-
Antibodies, Monoclonal, Humanized
-
Immunoconjugates
-
trastuzumab deruxtecan
-
Receptor, ErbB-2
-
Trastuzumab
-
Camptothecin